top of page

News & Events

Watch: The latest on our CAR-T technology at Myeloma Australia’s 4th Workshop

21 December 2022

21/12/22

Watch: Our CSO Rosanne Dunn presenting on our novel antigens LMA and KMA

20 December 2022

20/12/22

Watch: What makes our immunotherapies different on the growing myeloma treatment market

15 December 2022

15/12/22

AusBiotech 2022: HaemaLogiX CEO Bryce Carmine to present

17 October 2022

17/10/22

Watch: Everything you need to know about HaemaLogiX right now, CEO interview

12 October 2022

12/10/22

HaemaLogiX’s CAR-Ts to feature at 4th National Myeloma Workshop

11 October 2022

11/10/22

HaemaLogiX announces issuance of US patent for LMA

27 September 2022

27/9/22

Watch: Chief Manufacturing and Development Officer Tertia Dex explains the KappaMab manufacturing process

15 August 2022

15/8/22

HaemaLogiX strengthens Board with appointment of Dr. Geoff Nichol

7 July 2022

7/7/22

HaemaLogiX announces issuance of USA patent for KMA.CAR T

7 July 2022

7/7/22

HaemaLogiX and Lonza Collaborate to Manufacture KappaMab, a Multiple Myeloma Drug Candidate

27 January 2022

27/1/22

HaemaLogiX welcomes Tertia Dex to the team

17 January 2022

17/1/22

HaemaLogiX welcomes Professor Simon Harrison to the SAB

21 December 2021

21/12/21

Full presentation materials on the novel antigens LMA and KMA at the 63rd annual ASH meeting are now available

15 December 2021

15/12/21

Dr Mary Sartor to present research on LMA and the 10B3 monoclonal antibody developed by HaemaLogiX at ASH 2021

5 November 2021

5/11/21

Platinum leads immuno-oncology company HaemaLogiX’s $10m capital-raising round

12 September 2021

12/9/21

HaemaLogiX raises $10 million to advance multiple myeloma treatments

8 September 2021

8/9/21

HaemaLogiX announces collaboration with the Peter MacCallum Cancer Centre

5 February 2021

5/2/21

Orphan Drug Designation for KappaMab transferred to HaemaLogiX

29 January 2021

29/1/21

HaemaLogiX announces issuance of Australian patent for LMA

22 January 2021

22/1/21

HaemaLogiX Announces the Outcomes of Two Innovation Connections Grant Projects

16 October 2020

16/10/20

Bryce Carmine to present at AusBiotech & Invest 2020

9 October 2020

9/10/20

HaemaLogiX announces results of collaboration with CellVec

2 October 2020

2/10/20

HaemaLogiX announces issuance of Australian patent for KMA.CAR

25 September 2020

25/9/20

Prof Andrew Spencer presents KappaMab Phase 2b interim analysis results at ASH 2019

8 December 2019

8/12/19

HaemaLogiX initiates collaboration with Universidad de Navarra

5 November 2019

5/11/19

HaemaLogiX initiates collaboration with TPL Path Labs

7 May 2019

7/5/19

KMA.CAR-T cell preclinical data poster presentation at AACR 2018

16 April 2018

16/4/18

bottom of page